Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reveal Transition: Rivaroxaban-Evaluation of Variables Enhancing Antithrombotic Efficacy and Longterm-Outcome in Stabilized Patients With Cardiovascular Disease. A Mechanistic Study in Transition / Stabilized Phase of CAD

Next Previous
Search
Trial Profile

Reveal Transition: Rivaroxaban-Evaluation of Variables Enhancing Antithrombotic Efficacy and Longterm-Outcome in Stabilized Patients With Cardiovascular Disease. A Mechanistic Study in Transition / Stabilized Phase of CAD

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 19 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin
  • Indications Acute coronary syndromes; Atherosclerosis; Coronary artery disease; Peripheral arterial disorders
  • Focus Pharmacodynamics
  • Acronyms RevealTrans

    • Most Recent Events

    • 13 Jul 2022 Planned primary completion date changed from 1 Oct 2021 to 1 May 2020.
    • 13 Jul 2022 Status changed from recruiting to withdrawn prior to enrolment.
    • 26 Jul 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top